Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia
Lin-ling Cheng,Wei-jie Guan,Chong-yang Duan,Nuo-fu Zhang,Chun-liang Lei,Yu Hu,Ai-lan Chen,Shi-yue Li,Chao Zhuo,Xi-long Deng,Fan-jun Cheng,Yong Gao,Jian-heng Zhang,Jia-xing Xie,Hong Peng,Ying-xian Li,Xiao-xiong Wu,Wen Liu,Hui Peng,Jian Wang,Guang-ming Xiao,Ping-yan Chen,Chun-yan Wang,Zi-feng Yang,Jin-cun Zhao,Nan-shan Zhong
DOI: https://doi.org/10.1001/jamainternmed.2020.5503
2021-01-01
JAMA Internal Medicine
Abstract:<h3>Importance</h3><p>Lymphopenia is common and correlates with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19).</p><h3>Objective</h3><p>To determine whether a therapy that increases peripheral blood leukocyte and lymphocyte cell counts leads to clinical improvement in patients with COVID-19.</p><h3>Design, Setting and Participants</h3><p>Between February 18 and April 10, 2020, we conducted an open-label, multicenter, randomized clinical trial at 3 participating centers in China. The main eligibility criteria were pneumonia, a blood lymphocyte cell count of 800 per μL (to convert to ×10<sup>9</sup>/L, multiply by 0.001) or lower, and no comorbidities. Severe acute respiratory syndrome coronavirus 2 infection was confirmed with reverse-transcription polymerase chain reaction testing.</p><h3>Exposures</h3><p>Usual care alone, or usual care plus 3 doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2).</p><h3>Main Outcomes and Measures</h3><p>The primary end point was the time from randomization to improvement of at least 1 point on a 7-category disease severity score.</p><h3>Results</h3><p>Of 200 participants, 112 (56%) were men and the median (interquartile range [IQR]) age was 45 (40-55) years. There was random assignment of 100 patients (50%) to the rhG-CSF group and 100 (50%) to the usual care group. Time to clinical improvement was similar between groups (rhG-CSF group median of 12 days (IQR, 10-16 days) vs usual care group median of 13 days (IQR, 11-17 days); hazard ratio, 1.28; 95% CI, 0.95-1.71;<i>P</i> = .06). For secondary end points, the proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock was lower in the rhG-CSF group (rhG-CSF group, 2% vs usual care group, 15%; difference, −13%; 95%CI, −21.4% to −5.4%). At 21 days, 2 patients (2%) had died in the rhG-CSF group compared with 10 patients (10%) in the usual care group (hazard ratio, 0.19; 95%CI, 0.04-0.88). At day 5, the lymphocyte cell count was higher in the rhG-CSF group (rhG-CSF group median of 1050/μL vs usual care group median of 620/μL; Hodges-Lehmann estimate of the difference in medians, 440; 95% CI, 380-490). Serious adverse events, such as sepsis or septic shock, respiratory failure, and acute respiratory distress syndrome, occurred in 29 patients (14.5%) in the rhG-CSF group and 42 patients (21%) in the usual care group.</p><h3>Conclusion and Relevance</h3><p>In preliminary findings from a randomized clinical trial, rhG-CSF treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients developing critical illness or dying may have been reduced. Larger studies that include a broader range of patients with COVID-19 should be conducted.</p><h3>Trial Registration</h3><p>Chinese Clinical Trial Registry:ChiCTR2000030007</p>
medicine, general & internal